Orthopedic Surgery Doctors in Lufkin, TX Accepting Medicare

7 Orthopedic Surgery doctors found. Showing 1 - 7

Jason D Carter, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 208 Gaslight Blvd, Lufkin, TX 75904 Phone: 936-634-8800

Kristopher Blake Mccall, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 208 Gaslight Blvd, Lufkin, TX 75904 Phone: 936-638-8004

Dr. Roy Guse, M.D. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 208 Gaslight Blvd, Lufkin, TX 75904 Phone: 936-634-8800

Peter Wells Ross, M.D. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 208 Gaslight Blvd, Lufkin, TX 75904 Phone: 936-634-8800    Fax: 936-634-8836

Dr. Daniel Fuentes, D.O. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 208 Gaslight Blvd, Lufkin, TX 75904 Phone: 936-634-8800

Dr. John Daniel Carter, M.D. Orthopaedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 208 Gaslight Blvd, Suite 2, Lufkin, TX 75904 Phone: 936-634-8800    Fax: 936-630-8875

Dr. Jackson D Wagnon, M.D. Orthopaedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 208 Gaslight Blvd, Lufkin, TX 75904 Phone: 936-634-8800

News Archive

State Medicaid expansion: Consequences for coverage, death rate and bottom lines

States consider what myriad of consequences a Medicaid expansion could have. In Florida, a new study has leaders wondering how many lives could be saved by expansion. Meanwhile, as many as 182,000 Iowans could gain coverage under the plan. Also, Georgia considers cuts to the program.

John Theurer Cancer Center plays major role in FDA's fast tracking of ipilimumab for metastatic melanoma

Researchers from the John Theurer Cancer Center at Hackensack University Medical Center played an important role in a study that led to the Food & Drug Administration's (FDA) recent fast tracking of ipilimumab, a promising treatment for metastatic melanoma. The FDA based its decision largely on the results of a pivotal study published in the New England Journal of Medicine on August 19, 2010 – the same day the agency accepted Bristol-Myers Squibb's application for the drug's approval and granted the application priority review status.

Selling insurance across state lines: Still a partisan fight

Kaiser Health News staff writers Phil Galewitz and Lexie Verdon report: "When Republican House leaders recently unveiled their 'Pledge To America,' they revived an idea long popular with conservatives: legislation that would allow consumers to buy health insurance across state lines so that residents of a state with expensive health plans could find cheaper options elsewhere" (Galewitz and Verdon, 9/30).

New capsule, made from fish gelatin, should end fears of viral infections such as BSE and vCJD

An alternative to mammalian gelatin for use in pharmaceutical soft capsules has been discovered by researchers at the School of Pharmacy and Chemistry at Liverpool John Moores University.

FDA extends review of Genasense NDA appeal in chronic lymphocytic leukemia

Genta Incorporated has announced that the Food and Drug Administration (FDA) has extended its review of Genta's appeal of the non- approvable decision for a New Drug Application (NDA) that proposed the use of Genasense (oblimersen sodium injection) plus chemotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.

Read more Medical News

› Verified 7 days ago